GoAI
Get started
Alpha Cognition Inc logo

Alpha Cognition Inc

ACOG

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.75

+$0.25 · +2.63%

Aug 21, 4:00 PM ET

ACOG company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

71

Gaining

Sentiment

64

Bullish

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Michael E. McFadden
Listed since
Nov 12, 2024
Employees
71

Market position

Day range

Current $9.75

52-week range

Current $9.75

Open
$9.875
Previous close
$9.50
Volume
294.45K
4.01× average
Average volume
73.39K
Average daily volume
Market cap
151.43M USD
Beta
2.23
Market reference 1
50-day average
$7.9951
+21.95% above average
200-day average
$6.4328
+51.57% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
48.82M USD
P/E (TTM)
-8.93×
P/B (TTM)
4.01×
P/S (TTM)
9.92×
EV / EBITDA
-2.15×
Earnings yield
-17.99%
Free cash flow yield
-17.99%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
89.89%
Operating margin
-190.55%
Net margin
-153.61%
Return on equity
-33.06%
Return on assets
-25.92%
Return on invested capital
-32.10%

Financial health

Debt / equity
0×
Current ratio
8.65×

Financial statements

Income trends

Operating income

−22.66M USD-91.06%

Net income

−20.67M USD-41.22%
Income trends across reported periods−8.09M USD−14.21M USD−20.32M USD−26.44M USDOperating income, FY2021: −14.74M USDOperating income, FY2022: −18.09M USDOperating income, FY2023: −9.62M USDOperating income, FY2024: −11.86M USDOperating income, FY2025: −22.66M USDNet income, FY2021: −24.91M USDNet income, FY2022: −16.28M USDNet income, FY2023: −13.77M USDNet income, FY2024: −14.64M USDNet income, FY2025: −20.67M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −14.74M USD. Operating income FY2022 −18.09M USD. Operating income FY2023 −9.62M USD. Operating income FY2024 −11.86M USD. Operating income FY2025 −22.66M USD. Net income FY2021 −24.91M USD. Net income FY2022 −16.28M USD. Net income FY2023 −13.77M USD. Net income FY2024 −14.64M USD. Net income FY2025 −20.67M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue10.22M USD————
Cost of goods sold1.92M USD————
Gross profit8.3M USD————
Research and development1.87M USD3.92M USD5M USD11.85M USD10.16M USD
Selling, general, and administrative29.08M USD7.32M USD4.69M USD5.44M USD4.31M USD
Operating expenses30.97M USD11.86M USD9.62M USD18.09M USD14.74M USD
Interest income1.9M USD161.66K USD6.8K USD2.59K USD2.64K USD
Interest expense—185.78K USD67.71K USD232.29K USD673.13K USD
Depreciation and amortization58.57K USD81.22K USD84.48K USD122.17K USD114.55K USD
Operating income−22.66M USD−11.86M USD−9.62M USD−18.09M USD−14.74M USD
Net income−20.67M USD−14.64M USD−13.77M USD−16.28M USD−24.91M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
56%
5 beats, 4 misses, 0 met estimates
Average EPS surprise
+25.49%
9 comparable reports
Latest EPS result
-0.4
Estimate -0.39 · Miss by 2.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.07-0.28-0.49-0.7Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.51, estimate -0.48, surprise -6.25%, Miss. Q2 2025, reported May 15, 2025: actual -0.2, estimate -0.58, surprise +65.52%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.65, estimate -0.46, surprise -41.30%, Miss. Q4 2025, reported Nov 13, 2025: actual -0.082, estimate -0.43, surprise +81.02%, Beat. Q1 2026, reported Mar 26, 2026: actual -0.3, estimate -0.27, surprise -11.11%, Miss. Q2 2026, reported May 14, 2026: actual -0.37, estimate -0.41, surprise +9.76%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.4, estimate -0.392, surprise -2.00%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.33, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates7.56M5.18M2.8M425KQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q2 2025, reported May 15, 2025: actual 2.91M USD, estimate 500K USD, surprise +482.90%, Beat. Q3 2025, reported Aug 14, 2025: actual 1.66M USD, estimate 4.16M USD, surprise -60.11%, Miss. Q4 2025, reported Nov 13, 2025: actual 2.8M USD, estimate 2.03M USD, surprise +37.76%, Beat. Q1 2026, reported Mar 26, 2026: actual 2.8M USD, estimate 3.2M USD, surprise -12.54%, Miss. Q2 2026, reported May 14, 2026: actual 3.53M USD, estimate 3.42M USD, surprise +3.25%, Beat. Q3 2026, reported Aug 13, 2026: actual 6M USD, estimate 4.38M USD, surprise +36.86%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 7.04M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$17.25

76.92% upside
Past 12 months12-month forecastHigh $20.00Average $17.25Low $12.00

Corporate actions

Corporate action history

Stock split

Effective Nov 5, 2024

1:25

ACOG peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ACOG

research.disclaimer